InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+17.4%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Doyle Anthony, Chief Financial Officer. Director active across 1 company, notably Biocryst Pharmaceuticals INC. Cumulatively, 11 disclosures have been recorded. Breakdown: 2 buys · 1 sell. Total volume traded: €637k. History available since 23 November 2021. The latest transaction was disclosed on 19 December 2024 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Doyle Anthony
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
120,700 shares0Common StockSEC:0001127602-24-029965:0
2,461 shares@ US$7.391.6% of flowCommon StockSEC:0001127602-24-029965:1
7,890 shares@ US$7.535.1% of flowCommon StockSEC:0001127602-24-029573:0
36,300 shares@ US$5.5716.8% of flowCommon StockSEC:0001127602-24-015373:0
Canonical exit: 12 Aug 2024 (T+90)
2,482 shares@ US$6.051.2% of flowCommon StockSEC:0001127602-23-030181:0
34,000 shares0Common StockSEC:0001127602-23-029831:0
34,000 shares0Common StockSEC:0001127602-22-028074:0
5,700 shares@ US$10.905.2% of flowCommon StockSEC:0001127602-22-027883:0
75,000 shares0Common StockSEC:0001127602-22-001456:0
115,000 shares0Common StockSEC:0001127602-21-031121:0
35,258 shares@ US$12.4854.0% of flowCommon StockSEC:0001171843-21-008176:0
Canonical exit: 21 Feb 2022 (T+90)
11 of 11 declarations
About Doyle Anthony
Doyle Anthony is Chief Financial Officer at Biocryst Pharmaceuticals INC (XNAS). He has 11 filings in total, and across the sampled recent filings they span 2021-11-24 to 2024-12-23, with buy amounts of EUR 578364 and sell amounts of EUR 58194; the modal transaction nature is Attribution.
